Vanguard Group Inc reports 58.22% increase in ownership of KPRX / Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc.

US ˙ NasdaqCM

Security	KPRX / Kiora Pharmaceuticals, Inc.
Institution	Vanguard Group Inc
Latest Disclosed Ownership	33,091 shares
Latest Disclosed Value	$ 65,189

On January 29, 2026 - Vanguard Group Inc filed a 13F-HR form disclosing ownership of 33,091 shares of Kiora Pharmaceuticals, Inc. (US:KPRX) valued at $65,189 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 7, 2025 disclosing 20,915 shares of Kiora Pharmaceuticals, Inc.. This represents a change in shares of 58.22% during the quarter. The current value of the position is $82,728 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-01-29	2025-12-31	13F	KIORA PHARMACEUTICALS	COM	49721T507	33,091	12,176	58.22	65	12.07	0.0000
2025-11-07	2025-09-30	13F	KIORA PHARMACEUTICALS	COM	49721T507	20,915	20,915		59		0.0000
2022-02-14	2021-12-31	13F	EYEGATE PHARMACEUTICALS	COM NEW	30233M503	0	-151,702	-100.00	0	-100.00
2021-11-12	2021-09-30	13F	EYEGATE PHARMACEUTICALS	COM NEW	30233M503	151,702	23,935	18.73	341	-26.67	0.0000
2021-08-13	2021-06-30	13F	EYEGATE PHARMACEUTICALS	COM NEW	30233M503	127,767	84,227	193.45	465	114.29	0.0000
2021-05-14	2021-03-31	13F	EYEGATE PHARMACEUTICALS	COM NEW	30233M503	43,540	20,265	87.07	217	88.70	0.0000
2021-02-12	2020-12-31	13F	EYEGATE PHARMACEUTICALS	COM NEW	30233M503	23,275	11,602	99.39	115	150.00	0.0000
2020-11-16	2020-09-30	13F	EYEGATE PHARMACEUTICALS	COM NEW	30233M503	11,673	0	0.00	46	-17.86	0.0000
2020-08-14	2020-06-30	13F	EYEGATE PHARMACEUTICALS	COM NEW	30233M503	11,673	11,673		56		0.0000
2019-11-14	2019-09-30	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	0	-163,442	-100.00	0	-100.00
2019-08-14	2019-06-30	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	163,442	31,832	24.19	39	-2.50	0.0000
2019-05-15	2019-03-31	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	131,610	0	0.00	40	-34.43	0.0000
2019-02-14	2018-12-31	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	131,610	16,200	14.04	61	69.44	0.0000
2018-12-13	2018-09-30	13F/A-2	EYEGATE PHARMACEUTICALS	COM	30233M107	115,410	461	0.40	36	-40.98	0.0000
2018-11-23	2018-09-30	13F/A-1	EYEGATE PHARMACEUTICALS	COM	30233M107	115,410	0		36		0.0000
2018-11-14	2018-09-30	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	115,410	461		36
2018-08-14	2018-06-30	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	114,949	41,000	55.44	61	117.86	0.0000
2018-05-15	2018-03-31	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	73,949	-194,170	-72.42	28	-90.24	0.0000
2018-02-14	2017-12-31	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	268,119	0	0.00	287	-8.60	0.0000
2017-11-14	2017-09-30	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	268,119	20,800	8.41	314	-7.37	0.0000
2017-08-24	2017-06-30	13F/A-1	EYEGATE PHARMACEUTICALS	COM	30233M107	247,319	1,988	0.81	339	-45.85	0.0000
2017-08-11	2017-06-30	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	247,319	1,988		339
2017-05-12	2017-03-31	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	245,331	120,184	96.03	626	206.86	0.0000
2017-02-14	2016-12-31	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	125,147	50,237	67.06	204	56.92	0.0000
2016-11-14	2016-09-30	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	74,910	10,903	17.03	130	-21.69	0.0000
2016-08-10	2016-06-30	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	64,007	0	0.00	166	-15.74	0.0000
2016-05-13	2016-03-31	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	64,007	51,154	397.99	197	462.86	0.0000
2016-02-08	2015-12-31	13F	EYEGATE PHARMACEUTICALS	COM	30233M107	12,853	12,853		35		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.